	Application No.	Applicant(s)
Notice of Allowability	10/666,068	BUETTNER ET AL.
	Examiner	Art Unit
	Brian J. Davis	1621
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to and MPEP 1308.	olication. If not included will be mailed in due course. THIS
1. This communication is responsive to applicant's amendment (3/23/05).		
2. The allowed claim(s) is/are 10-40 [renumbered 1-31].		
3. The drawings filed on are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority una a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	been received. been received in Application No	
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give		
6. CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	on's Patent Drawing Review (PTO-s Amendment / Comment or in the O 84(c)) should be written on the drawin	ffice action of gs in the front (not the back) of
7. DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT Report of the comment regarding Report of the comm		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Summary Paper No./Mail Date 8), 7. ⊠ Examiner's Amendm	e <u>attached</u> .

Art Unit: 1621

DETAILED ACTION

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Andrea Small on 5/9/05.

The application has been amended as follows:

In claim 16, the dependency has been changed from claim "13" to claim -- 15--.

Art Unit: 1621

102 Rejections Withdrawn

The rejections of claims 1, 8 and 9 under 35 USC 102(b), outlined in the previous Office Action, have been overcome by applicant's amendment. The amendment cancels the claims.

103 Rejections Withdrawn

The rejections of claims 1-9 under 35 USC 103(a), outlined in the previous Office Action, have been overcome by applicant's amendment. The amendment cancels the claims.

Claim Objections Withdrawn

The objection to claims 10-16, as being objected to because they depended from a rejected base claim but otherwise allowable, is withdrawn. Applicant's amendment recasts the pertinent claims within the group of 10-16 as independent claims.

Allowable Subject Matter

Claims 10-40 are allowed. The following is an examiner's statement of reasons for allowance:

The closest prior art appears to be US 3,657,244, prior art of record. The reference teaches a set of the instant compounds within a larger set of structurally related compounds which exhibit bronchospasmolytic and antipruritic activities and that

Art Unit: 1621

dilate the peripheral blood vessels in warm-blooded animals such as mice and rats (column 12 line 72). The cited prior art neither teaches nor suggests, however, the instant methods (treatment of asthma, COPD, tocolysis, etc.) or compositions. Nor would it have been obvious to one of ordinary skill in the art at the time of invention to modify the teachings of the prior art in order to arrive at those of the instant invention. There is no motivation to do so.

At best, it might have been obvious to try the prior art compounds in the treatment of asthma, COPD, tocolysis, etc., however, an 'obvious to try' standard is impermissible in two situations: 1) where the prior art gives no indication as to which of numerous parameters are critical, or gives no indication as to which of many possible choices is likely to be successful; and 2) where the prior art gives only general guidance with respect to the form of the invention but not how to achieve it new areas of technology or in fields of experimentation which are only seemingly promising. *In re O'Farrell*, 853 F2d 894, 7 USPQ 2d 1673, 1681 (Fed. Cir. 1988). In the instant case, both 1 and 2, above, apply.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1621

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian J. Davis whose telephone number is 571-272-0638. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Brian J. Davis May 9, 2005